Effect of Ruboxistaurin on Visual Loss in Patients with Diabetic Retinopathy

Ophthalmology

Volumn 113, Issue 12, 2006, Pages 2221-2230

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STEREOSCOPIC VISION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT; VISUAL SYSTEM EXAMINATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; DIABETIC RETINOPATHY; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; MACULAR EDEMA, CYSTOID; MALE; MALEIMIDES; MIDDLE AGED; PROTEIN KINASE C; VISION DISORDERS; VISUAL ACUITY;

EID: 33751520614     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.07.032     Document Type: Article

References (43)

1. Centers for Disease Control and Prevention (CDC). Blindness caused by diabetes-Massachusetts, 1987-1994. MMWR Morb Mortal Wkly Rep 45 (1996) 937-941
2. Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 122 (2004) 552-563
3. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 91 (1984) 1464-1474
4. Williams R., Airey M., Baxter H., et al. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 18 (2004) 963-983
5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
7. Sheetz M.J., and King G.L. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288 (2002) 2579-2588
8. Shore A.C. The microvasculature in type 1 diabetes. Semin Vasc Med 2 (2002) 9-20
9. Inoguchi T., Battan R., Handler E., et al. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 89 (1992) 11059-11063
10. Aiello L.P., Bursell S.E., Clermont A., et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46 (1997) 1473-1480
11. Xu X., Zhu Q., Xia X., et al. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res 28 (2004) 251-256
12. Danis R.P., Bingaman D.P., Jirousek M., and Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 39 (1998) 171-179
13. Aiello L.P., Clermont A., Arora V., et al. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 47 (2006) 86-92
14. Funatsu H., Yamashita H., Ikeda T., et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110 (2003) 1690-1696
15. Suzuma K., Takahara N., Suzuma I., et al. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci U S A 99 (2002) 721-726
16. Ishii H., Jirousek M.R., Koya D., et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272 (1996) 728-731
17. Koya D., Haneda M., Nakagawa H., et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14 (2000) 439-447
18. Cotter M.A., Jack A.M., and Cameron N.E. Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond) 103 (2002) 311-321
19. Kelly D.J., Zhang Y., Hepper C., et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52 (2003) 512-518
20. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 98 (1991) 741-756
21. PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54 (2005) 2188-2197
22. Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment Diabetic Retinopathy Study. Manual of Operations (1985), National Eye Institute, Bethesda, MD 12-1-67
23. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 98 (1991) 786-806
24. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98 (1991) 823-833
25. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (1985) 1796-1806
26. Nakamura J., Kato K., Hamada Y., et al. A protein kinase C beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 48 (1999) 2090-2095
27. Campochiaro P.A., and C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 45 (2004) 922-931
28. Moss S.E., Klein R., and Klein B.E. The incidence of vision loss in a diabetic population. Ophthalmology 95 (1988) 1340-1348
29. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report no. 4. Int Ophthalmol Clin 27 (1987) 265-272
30. UK Prospective Diabetes Study (UKPDS) Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 122 (2004) 1631-1640
31. Shiba T., Inoguchi T., Sportsman J.R., et al. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 265 (1993) E783-E793
32. Yuan S.Y., Ustinova E.E., Wu M.H., et al. Protein kinase C activation contributes to microvascular barrier dysfunction in the heart at early stages of diabetes. Circ Res 87 (2000) 412-417
33. Saishin Y., Saishin Y., Takahashi K., et al. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. J Cell Physiol 195 (2003) 210-219
34. Chen M.L., Pothoulakis C., and LaMont J.T. Protein kinase C signaling regulates ZO-1 translocation and increased paracellular flux of T84 colonocytes exposed to Clostridium difficile toxin A. J Biol Chem 277 (2002) 4247-4254
35. Lacaz-Vieira F., and Jaeger M.M. Protein kinase inhibitors and the dynamics of tight junction opening and closing in A6 cell monolayers. J Membr Biol 184 (2001) 185-196
36. Antonetti D.A., Barber A.J., Khin S., et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occluding content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 47 (1998) 1953-1959
37. Kowluru R.A., Jirousek M.R., Stramm L., et al. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. V. Relationship between protein kinase C and ATPases. Diabetes 47 (1998) 464-469
38. Coppelli A., Giannarelli R., Vistoli F., et al. The beneficial effects of pancreas transplant alone on diabetic nephropathy. Diabetes Care 28 (2005) 1366-1370
39. Mann J.F.E., Gerstein H.C., Yi Q.L., et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 14 (2003) 641-647
40. Mann J.F.E., Gerstein H.C., Yi Q.L., et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis 42 (2003) 936-942
41. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
42. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: 30-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol. In press.
43. Tuttle K.R., Bakris G.L., Toto R.D., et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28 (2005) 2686-2690